Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.
Avcı O, İriağaç Y, Çavdar E, Karaboyun K, Araz M, Şakalar T, Değerli E, Özdemir Ö, İnal A, Ocak B, Ürün M, Sakin A, Yıldız Tacar S, Koçak MZ, Demir H, Özer Ö, Tanrıkulu Şimşek E, Ersoy M, Karakaş Y, Arıkan R, Eşbah O, Ön S, Şenocak Taşçı E, Molinas Mandel N, Türker S, Kaçan T, Yıldırım HÇ, Alan Ö, Akbaş S, İpek Deniz G, Aydın İsak Ö, Taşkaynatan H, Şeber ES. Avcı O, et al. Among authors: taskaynatan h. J Geriatr Oncol. 2023 Nov;14(8):101604. doi: 10.1016/j.jgo.2023.101604. Epub 2023 Sep 6. J Geriatr Oncol. 2023. PMID: 37683369
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Bilgin B, et al. Among authors: taskaynatan h. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433657
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Erol C, Sendur Mehmet AN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Erol C, et al. Among authors: taskaynatan h. J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. J Cancer Res Ther. 2022. PMID: 36510987 Free article. Clinical Trial.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Özdemir Ö, Zengel B, Yildiz Y, Uluç BO, Cabuk D, Ozden E, Salim DK, Paydas S, Demir A, Diker O, Pilanci KN, Sönmez ÖU, Vatansever S, Dogan I, Gulmez A, Cakar B, Gursoy P, Yildirim ME, Ayhan M, Karadurmus N, Aykan MB, Cevik GT, Sakalar T, Hacibekiroglu I, Gülbagci BB, Dincer M, Garbioglu DB, Kemal Y, Nayir E, Taskaynatan H, Yilmaz M, Avci O, Sari M, Coban E, Atci MM, Esen SA, Telli TA, Karatas F, Inal A, Demir H, Kalkan NO, Yilmaz C, Tasli F, Alacacioglu A. Özdemir Ö, et al. Among authors: taskaynatan h. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310. Epub 2022 Jun 20. Anticancer Drugs. 2022. PMID: 35703239
Prevalence and related factors of sarcopenia in newly diagnosed cancer patients.
Oflazoglu U, Alacacioglu A, Varol U, Kucukzeybek Y, Salman T, Taskaynatan H, Yildiz Y, Ozdemir O, Tarhan M. Oflazoglu U, et al. Among authors: taskaynatan h. Support Care Cancer. 2020 Feb;28(2):837-843. doi: 10.1007/s00520-019-04880-4. Epub 2019 Jun 3. Support Care Cancer. 2020. PMID: 31161438
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Tural D, et al. Among authors: taskaynatan h. Int J Clin Oncol. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. Int J Clin Oncol. 2021. PMID: 34023933
Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review.
Ozdemir O, Zengel B, Yildiz Y, Saray S, Alacacioglu A, Tasli F, Can Erdi Z, Oflazoglu U, Taskaynatan H, Salman T, Varol U, Hilal Adibelli Z, Durusoy R, Kucukzeybek Y. Ozdemir O, et al. Among authors: taskaynatan h. Sisli Etfal Hastan Tip Bul. 2021 Dec 29;55(4):503-509. doi: 10.14744/SEMB.2021.66503. eCollection 2021. Sisli Etfal Hastan Tip Bul. 2021. PMID: 35317367 Free PMC article.
Is Monitoring Mean Platelet Volume Necessary in Breast Cancer Patients?
Taskaynatan H, Alacacioglu A, Kucukzeybek Y, Varol U, Yildiz Y, Salman T, Oflazoglu U, Tarhan MO. Taskaynatan H, et al. Open Med (Wars). 2018 Oct 4;13:450-455. doi: 10.1515/med-2018-0067. eCollection 2018. Open Med (Wars). 2018. PMID: 30426082 Free PMC article.
23 results